Panel raised questions about Afrezza's commercial outlook, says Piper Jaffray Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock.
MannKind triples production capacity for Afrezza MannKind announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.